Biosergen publishes interim report for third quarter 2023
Thursday, November 30, 2023: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q3 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | July-Sep | July-Sep | Jan-Sept | Jan-Sep | Jan-Dec |
| Profit/loss | |||||
| Other income | 292 | 493 | 8.063 | 3.219 | 5.183 |
| Profit/loss before depreciation (EBITDA | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Operating profit/loss befor net financials | -7.537 | -14.515 | -20.604 | -27.496 | -34.129 |
| Net financials | 27 | 16 | 36 | 22 | 81 |
| Netprofit/loss for the period | -7.510 | -14.499 | -20.568 | -27.474 | -34.048 |
| Earnings per share (SEK) | -0,15 | -0,51 | -0,48 | -0,97 | -1,09 |
Highlights during Q3 2023
- September 25, Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections.
- August 28, Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million.
- August 16, Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management.
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11).
Highlights after the period
- Abstract presented at the 11th Trends in Medical Mycology publicly available
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).
ABOUT BIOSERGEN
Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to test the drug in patients expected to clinically validate BSG005’s potential as a new and strong antifungal treatment. Biosergen’s development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit www.biosergen.net.